MNPR Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Monopar Therapeutics's net margin of 10.05%. Monopar Therapeutics's return on equity of -- beat Electromed's return on equity of 15.62%.

Monopar Therapeutics has a consensus price target of $32.00, signalling upside risk potential of 35.59%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 8.91%. Given that Monopar Therapeutics has higher upside potential than Electromed, analysts believe Monopar Therapeutics is more attractive than Electromed.

Monopar Therapeutics has a beta of 1.229, which suggesting that the stock is 22.881% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Monopar Therapeutics's net income of -$1.3M is lower than Electromed's net income of $1.5M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 42.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 4.73x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Monopar Therapeutics's net margin of -10.5%. Monopar Therapeutics's return on equity of -- beat Myomo's return on equity of -84.04%.

Monopar Therapeutics has a consensus price target of $32.00, signalling upside risk potential of 35.59%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 12.25%. Given that Monopar Therapeutics has higher upside potential than Myomo, analysts believe Monopar Therapeutics is more attractive than Myomo.

Monopar Therapeutics has a beta of 1.229, which suggesting that the stock is 22.881% more volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.2M. Monopar Therapeutics's net income of -$1.3M is lower than Myomo's net income of -$966.4K. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 9.98x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Monopar Therapeutics's net margin of -4291.67%. Monopar Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Monopar Therapeutics has a consensus price target of $32.00, signalling upside risk potential of 35.59%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 257.14%. Given that Catheter Precision has higher upside potential than Monopar Therapeutics, analysts believe Catheter Precision is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.229, which suggesting that the stock is 22.881% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Monopar Therapeutics's net income of -$1.3M is higher than Catheter Precision's net income of -$4.1M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 1.49x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Monopar Therapeutics's net margin of -17.98%. Monopar Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Monopar Therapeutics has a consensus price target of $32.00, signalling upside risk potential of 35.59%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 338.43%. Given that Xtant Medical Holdings has higher upside potential than Monopar Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Monopar Therapeutics.

Monopar Therapeutics has a beta of 1.229, which suggesting that the stock is 22.881% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Monopar Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Monopar Therapeutics's net income of -$1.3M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.60x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.